Mylan Receives Approval for Generic Version of Neurontin Tablets

Mylan announced that its subsidiary Matrix Laboratories has received final approval from the FDA for its Abbreviated New Drug Application for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of Pfizer’s Neurontin Tablets for the treatment of postherpetic neuralgia, a complication of shingles.
MarketWatch